Finally, 77 cases of intrahepatic cholangiocarcinoma (ICC) were collected for verification. Cholangiocarcinoma is the second most common primary malignant liver tumor. The incidence rate and mortality ...

The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.

Intrahepatic cholangiocarcinoma is a highly malignant tumor with a poor prognosis. Radical surgical resection remains the “gold standard” for improving patient outcomes; however, only a minority of ...

Clinical landscape of cell free DNA alterations in patients with advanced biliary tract cancer treated with targeted therapies.

Expression of Trop2, Nectin-4, and FOLR1 cell surface markers in biliary tract cancers: Is it time to repurpose drugs? This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

February is National Cancer Awareness Month, a time to amplify discussions on lesser- known but equally devastating ...

Some researchers have recommended that although the diagnosis of cholangiocarcinoma should ... we present 24 patients with intrahepatic bile duct dilation and no mass lesion demonstrated on ...

Hepatocellular carcinoma is the most common form of liver cancer. It can begin as a single tumor or multiple small tumors throughout the liver. Intrahepatic Cholangiocarcinoma A cancerous tumor in the ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

The Bismuth–Corlette classification system provides an anatomic description of the tumor location and longitudinal extension in the biliary tree (Figure 3). It is limited due to its failure to ...

TYRA is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3 ...